Evidence map›Paper›PMID 38178855›Full record

ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2024

Assessing medication adherence and their associated factors amongst type-2 diabetes mellitus patients of Jazan Province, Saudi Arabia: A single-center, cross-sectional study.

Amani Khardali, Nabeel Kashan Syed, Saad S Alqahtani, Marwa Qadri, Abdulkarim M Meraya, Norah Rajeh, Fatimah Aqeely, Sedan Alrajhi, Amnah Zanoom, Shahd Gunfuthi and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Hepatitis Associated withJournal of clinical medicine · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Amani KhardaliPharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jizan - 45142, Jazan, Saudi Arabia.
Nabeel Kashan SyedPharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jizan - 45142, Jazan, Saudi Arabia.
Saad S AlqahtaniDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Marwa QadriDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan-45142, Saudi Arabia.
Abdulkarim M MerayaPharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jizan - 45142, Jazan, Saudi Arabia.
Norah RajehJazan Endocrinology and Diabetes Centre, Jizan - 82723, Jazan, Saudi Arabia.
Fatimah AqeelyJazan Endocrinology and Diabetes Centre, Jizan - 82723, Jazan, Saudi Arabia.
Sedan AlrajhiCollege of Pharmacy, Jazan University, Jizan - 45142, Saudi Arabia.
Amnah ZanoomCollege of Pharmacy, Jazan University, Jizan - 45142, Saudi Arabia.
Shahd GunfuthiCollege of Pharmacy, Jazan University, Jizan - 45142, Saudi Arabia.
Wahhaj BasudanCollege of Pharmacy, Jazan University, Jizan - 45142, Saudi Arabia.
Thana K HakamiFaculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.
Mawada A AbdelgadirPharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jizan - 45142, Jazan, Saudi Arabia.
Jazan University · SAKing Khalid University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The prevalence of type 2 diabetes mellitus (T2DM) globally is reaching epidemic proportions. By 2035, it is projected to increase to 417 million, which is of significant concern as T2DM represents the most oversized budget item in many healthcare systems, primarily due to the high rates of morbidity and mortality associated with the disease. The worldwide cost burden of T2DM has been inexorably growing. A key contributor to the remarkably high morbidity and mortality rates is poor glycemic control potentially associated with medication non-adherence. Aim: The present research's main objective included assessing medication adherence among patients with T2DM in a single center in Jazan Province. Methods: Three hundred nine patients with T2DM participated in a cross-sectional survey over three months (September to November 2022). The study participants comprised 50.8 % (females) and 49.2 % (males), with a mean age of 44.12 years (SD ± 12.70). A 31-item self-report questionnaire was used for data collection. Results: Sixty-six percent of the sample were found to be adherent to their T2DM therapy. A positive association was noticed between the GMAS score and the participant's age (r = 0.24; p < 0.01). The participants' medication adherence was significantly associated with having age above 50 years ( Conclusion: The majority of T2DM patients in the present study were found adherent to their anti-diabetic medications, particularly older patients. Future studies should focus on exploring the reasons for the reported high adherence among older patients and non-adherence among younger patients, as this could facilitate the development of a strategy to enhance adherence.

Indexed as

Jazan ProvinceMedication adherenceSaudi ArabiaType-2 diabetes mellitus

Identifiers

PMID38178855
PMCPMC10764249
OpenAlexW4389365377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.